An interventional study of Empowering Pain Psychology Access and Collaboration (EPPAC) and Usual Care Pain Psychology Evaluation in Chronic Low Back Pain (CLBP), sponsored by Johns Hopkins University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Low Back Pain by Johns Hopkins University — 3 open to participants now, 3 under way, none of them phase 3. Low Back Pain · Johns Hopkins University.
Among the 17 studies in Low Back Pain by Johns Hopkins University, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, and was the 17th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →3 of the 17 studies in Low Back Pain by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–64
Johns Hopkins University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 117 across the 16 interventional studies, 346 across the 1 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Low Back Pain by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic low back pain (cLBP) is a leading cause of disability, with socioeconomically disadvantaged populations experiencing worse outcomes and lower rates of treatment initiation for evidence-based pain psychology services. Participant engagement strategies such as shared decision-making (SDM) and motivational interviewing (MI) have shown promise in improving treatment uptake, but no study has examined whether integrating these approaches into a pain psychology evaluation can improve engagement among socioeconomically disadvantaged participants or offered participants a structured choice between cognitive behavioral therapy (CBT) and emotional awareness and expression therapy (EAET), presented to participants as Pain and Emotion Reprocessing Therapy (PERT). The Empowering Pain Psychology Access and Collaboration (EPPAC) intervention, a brief, psychologist-led engagement strategy combining SDM and MI within a standard pain psychology evaluation, was developed to address this gap.
Chronic low back pain (cLBP) is among the leading causes of disability worldwide, affecting approximately 12.8 million adults in the United States. Individuals with low socioeconomic status (SES) are disproportionately affected, with roughly twice the rate of developing cLBP compared with higher-SES populations. The investigator's prior work has shown that socioeconomically disadvantaged adults with cLBP report worse pain-related outcomes than more advantaged counterparts, underscoring the need for effective and accessible treatments in this population.
Clinical practice guidelines recommend nonpharmacological approaches, including pain psychology, as first-line treatments for cLBP. Among the most established pain psychology treatments is cognitive behavioral therapy (CBT), which targets maladaptive patterns of thinking and behavior that contribute to pain, disability, and distress. A growing evidence base also supports emotional awareness and expression therapy (EAET), presented to participants in REACH as Pain and Emotion Reprocessing Therapy (PERT). EAET is grounded in contemporary pain neuroscience and addresses emotional experiences, stress, and interpersonal processes that may contribute to chronic pain.
Despite the availability of these treatments, a substantial proportion of participants referred for pain psychology do not initiate treatment, with reported initiation rates ranging from 24% to 73%. Preliminary findings from the OPTIMIZE trial, a pragmatic comparative effectiveness study of nonpharmacological treatments for cLBP conducted across three US health systems, indicate that only 59% of participants randomized to CBT initiated treatment, with socioeconomic factors such as neighborhood deprivation emerging as significant predictors of non-initiation. These findings suggest that socioeconomically disadvantaged participants face distinct barriers to engaging with psychological treatments for pain, and that simply offering effective treatments is insufficient if participants do not start treatments.
Participant engagement strategies have shown promise in improving treatment uptake. Shared decision-making (SDM) supports informed choices by presenting treatment options alongside benefits and trade-offs in a structured, collaborative conversation. Motivational interviewing (MI) supports motivation by exploring ambivalence and strengthening commitment in a non-confrontational manner. A prior trial by the investigator's team demonstrated that a single-session MI intervention delivered during a clinical encounter increased participation in physical therapy, reduced disability, and improved health outcomes among adults undergoing surgery for degenerative lumbar spinal stenosis. More recently, the Equity Using Interventions for Pain and Depression (EQUIPD) pilot trial demonstrated that coaching paired with a decision aid to facilitate SDM about nonpharmacological pain treatments was feasible and showed improvements in shared decision-making, participant engagement, and therapeutic alliance among Black participants with chronic musculoskeletal pain. However, no study has examined whether integrating SDM and MI into a pain psychology evaluation can improve treatment initiation among socioeconomically disadvantaged participants, nor has any study offered participants a structured choice between CBT and EAET.
To address this gap, the Empowering Pain Psychology Access and Collaboration (EPPAC) intervention, a brief, psychologist-led engagement strategy designed to be embedded within a standard pain psychology evaluation, was developed. EPPAC combines MI techniques with a structured SDM framework to help participants understand how psychology relates to pain, explore whether treatment fits the participant's situation, and choose between CBT and EAET based on the participant's values and preferences. In participant-facing REACH materials, EAET is presented as Pain and Emotion Reprocessing Therapy (PERT). The purpose of this study is to evaluate the feasibility, acceptability, and preliminary effectiveness of EPPAC compared with usual care among Medicaid-insured adults with cLBP in a pilot randomized controlled trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive the standard pain psychology evaluation followed by the structured EPPAC engagement and shared decision-making process during the same scheduled telehealth appointment. EPPAC helps participants decide whether pain psychology fits their treatment plan and, if treatment is selected, choose between cognitive behavioral therapy (CBT) and emotional awareness and expression therapy (EAET), presented to participants as Pain and Emotion Reprocessing Therapy (PERT). Subsequent CBT or EAET/PERT treatment is routine clinical care and is available in both study arms.
Behavioral: Empowering Pain Psychology Access and Collaboration (EPPAC)
Participants receive the standard pain psychology evaluation and the clinic's usual discussion of treatment recommendations and available options, without the EPPAC-specific structured elements. CBT and EAET, presented to participants as PERT, remain available as clinically appropriate. Subsequent treatment is routine clinical care.
Behavioral: Usual Care Pain Psychology Evaluation
EPPAC is a brief, psychologist-led engagement strategy embedded within a standard pain psychology evaluation. It combines motivational interviewing and shared decision-making, structured pain education, a patient decision aid, two decision points, balanced discussion of CBT and EAET (presented to participants as PERT), and next-step planning to support informed engagement in pain psychology care.
Usual care consists of the clinic's standard pain psychology evaluation and usual discussion of clinical recommendations and treatment options. It does not include the EPPAC-specific decision aid, standardized EPPAC pain education, exact Decision Point 1 question, or EPPAC next-steps probe. CBT and EAET, presented to participants as PERT, are downstream clinical treatment options available in both study arms.
Percentage of participant and provider Acceptability of Intervention Measure (AIM) responses with a mean score of 4 or greater
The AIM is a 4-item measure scored on a 5-point Likert scale (1 = Completely disagree to 5 = Completely agree). A respondent-level mean score is calculated across the four items, with higher scores indicating greater acceptability. Participant and provider responses will be summarized separately. For this pilot, the prespecified study-defined acceptability benchmark is at least 70% of participant responses and at least 70% of provider responses with a mean AIM score of 4 or greater.
Time frame: Immediately following the initial evaluation appointment
Percentage of participant and provider Intervention Appropriateness Measure (IAM) responses with a mean score of 4 or greater
The IAM is a 4-item measure scored on a 5-point Likert scale (1 = Completely disagree to 5 = Completely agree). A respondent-level mean score is calculated across the four items, with higher scores indicating greater perceived appropriateness. The percentage of responses with a mean score of 4 or greater will be reported separately for participants and providers and interpreted descriptively; no pass/fail appropriateness threshold is prespecified.
Time frame: Immediately following the initial evaluation appointment
Proportion of EPPAC evaluations in which the required core EPPAC components were delivered as intended
Fidelity will be assessed using structured provider-completed documentation in Epic indicating completion of the core EPPAC stages and intervention components. For this pilot, the prespecified study-defined feasibility benchmark is delivery of the required EPPAC components in at least 70% of EPPAC evaluation visits. Sessions will not be recorded or independently coded for fidelity.
Time frame: Immediately following the initial evaluation appointment
Percentage of participant and provider Feasibility of Intervention Measure (FIM) responses with a mean score of 4 or greater
The FIM is a 4-item measure scored on a 5-point Likert scale (1 = Completely disagree to 5 = Completely agree). A respondent-level mean score is calculated across the four items, with higher scores indicating greater perceived feasibility. The percentage of responses with a mean score of 4 or greater will be reported separately for participants and providers and interpreted descriptively; the study's prespecified feasibility benchmark is based on EPPAC delivery fidelity rather than an FIM cutoff.
Time frame: Immediately following the initial evaluation appointment
Percentage of randomized participants initiating pain psychology treatment by 12 weeks
Treatment initiation is defined as attendance at least one cognitive behavioral therapy (CBT) or emotional awareness and expression therapy (EAET; presented to participants as PERT) treatment session documented in the electronic medical record (EMR) within 12 weeks. The denominator is all randomized participants, consistent with the intent-to-treat approach.
Time frame: 12 weeks
Total number of treatment sessions attended (out of 8 sessions)
Total number of treatment sessions attended will be determined using the EMR.
Time frame: 12 weeks
Participant's choice of treatment
Participant treatment decision at the end of the evaluation workflow, categorized as cognitive behavioral therapy (CBT), emotional awareness and expression therapy (EAET; presented to participants as PERT), or no treatment selected, assessed by randomized arm.
Time frame: Immediately following the initial evaluation appointment
Percentage of treatment initiators who discontinue treatment before completing 6 sessions
Among participants who initiate pain psychology treatment by attending at least one CBT or EAET/PERT session, treatment dropout is defined as discontinuing before completion of 6 treatment sessions within the 12-week treatment-engagement period. Treatment attendance will be determined using the EMR.
Time frame: 12 weeks
The frequency of participants who stated a preference for Cognitive Behavioral Therapy (CBT), Emotional Awareness and Expression Therapy (EAET; presented to participants as PERT), or were unsure.
Participants' stated treatment preference will be assessed using a single item completed prior to completion of the decisional conflict measure.
Time frame: Immediately following the initial evaluation appointment
Percentage of participants with decisional conflict on the Sure of myself, Understand information, Risk-benefit ratio, Encouragement (SURE) test
The SURE test is a 4-item binary screening measure derived from the Decisional Conflict Scale. Each item is scored 0 or 1, yielding a total score from 0 to 4. A score of 4 (better) indicates no decisional conflict; scores of 0 to 3 indicate decisional conflict.
Time frame: Immediately following the initial evaluation appointment
CollaboRATE shared decision-making score
CollaboRATE is a 3-item participant-reported measure of the shared decision-making process. Each item is scored from 0 (no effort was made) to 4 (every effort was made), yielding a total score from 0 to 12, with higher scores indicating greater shared decision-making. A top score is defined as the highest response on all three items and may also be reported as the proportion of participants achieving a top score.
Time frame: Immediately following the initial evaluation appointment
Participant openness to future engagement, assessed by arm and by treatment initiation status.
Participant openness to future engagement, assessed with an investigator-developed single item: "If my situation changes in the future, I would consider working with a psychologist for my pain." This item is rated on a 5-point agreement scale with higher scores indicating greater levels of openness to future engagement.
Time frame: Immediately following the initial evaluation appointment
Pain Self-Efficacy Questionnaire-Two-Item Short Form (PSEQ-2)
The Pain Self-Efficacy Questionnaire 2-item short form (PSEQ-2) assesses confidence in performing activities despite pain. Total scores range from 0 to 12, with higher scores indicating greater pain self-efficacy.
Time frame: Baseline, 12 weeks, and 24 weeks
Oswestry Disability Index (ODI)
The Oswestry Disability Index is a 10-item measure of low back pain-related disability across pain intensity and daily activities. Each item is scored from 0 to 5. The item scores are summed and converted to a percentage disability score ranging from 0% to 100%, with higher scores indicating greater disability.
Time frame: Screening, 12 weeks, and 24 weeks
Patient-Reported Outcome Measurement Information System (PROMIS-29+2 Profile v2.1 (PROPr))
The Patient-Reported Outcome Measurement Information System (PROMIS-29+2 Profile v2.1 \[PROPr\]) assesses 8 domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Pain Interference, and Cognitive Function-Abilities, in addition to a Pain Intensity item. The multi-item domains use 5-category response scales and are converted to standardized T-scores (mean = 50, standard deviation = 10); the Pain Intensity item is scored from 0 to 10. Higher T-scores indicate more of the construct being measured. For symptom domains such as Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Interference, higher scores indicate worse symptoms; for Physical Function and Ability to Participate in Social Roles and Activities, higher scores indicate better functioning.
Time frame: Baseline, 12 weeks, and 24 weeks
University of Washington Concerns About Pain Scale (UW-CAP) 6-item short form))
The University of Washington Concerns About Pain Scale 6-item short form (UW-CAP-6) assesses pain catastrophizing, described in the instrument as concerns about pain. Each item uses five response options coded from 1 to 5. The six item codes are summed only as an intermediate raw score (range 6 to 30) and then converted using the published concordance table to an item response theory (IRT)-based T-score. The T-score, rather than the raw sum, will be reported and analyzed. Higher T-scores indicate greater concerns about pain; the calibration metric has a mean of 50 and standard deviation of 10.
Time frame: Baseline, 12 weeks, and 24 weeks
Patient Global Impression of Change (PGIC)
The Patient Global Impression of Change (PGIC) is a single-item participant-reported measure of overall change in activity limitations, symptoms, emotions, and quality of life related to the painful condition. Responses are rated on a 7-point scale from 1 = No change (or condition has gotten worse) to 7 = A great deal better, with higher scores indicating greater perceived improvement. Scores of 5, 6, and 7 correspond to moderately better, better, and a great deal better, respectively.
Time frame: 12 weeks and 24 weeks
The STarT Back Screening Tool (SBST)
The STarT (Subgroups for Targeted Treatment) Back Screening Tool (SBST) was developed as a risk stratification tool for future persistent disabling low back pain. This tool is comprised of 9 items (scored 0 or 1 point). Scores range from 0 to 9. Participants with scores of 3 or lower may have a low risk for future persistent disabling low back pain and related activity limitations. Participants with scores of 4 or higher have an increased risk for these same outcomes. There is also a Psychosocial Distress Subscore that distinguishes between medium and high risk subgroups, based on the last five items of the tool. Participants with a Distress Subscore of 0-3 points are categorized as medium risk and those with a Distress Subscore of 4 or higher are considered high risk for persistent disabling back pain.
Time frame: Baseline
Plan to share: Yes — De-identified data will be deposited in the Inter-university Consortium for Political and Social Research (ICPSR). The dataset will consist of: participant study identification number, treatment arm assignment, coarsened demographic variables (age range, sex, race and ethnicity, insurance type), responses to validated survey instruments at each assessment timepoint, session attendance counts, and treatment initiation and completion status. During the oral consent process, the study coordinator asks each participant whether the participant agrees to have their de-identified data deposited in a public research data repository. The response is recorded in REDCap at the time of consent. Participants who decline are enrolled and participate in all study activities without restriction; their records are flagged and excluded from the deposit.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: De-identified individual participant data and associated documentation will be made available through ICPSR after completion of the study, final data cleaning, and publication of the primary study findings, in accordance with NIH, Johns Hopkins University, and ICPSR requirements. Data will remain available according to ICPSR repository policies.
Access criteria: De-identified data will be shared through ICPSR in accordance with the repository's applicable access and data-use procedures. Only data from participants who agreed during the consent process to repository sharing will be included. Direct identifiers will not be shared.
Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.
Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 21 months is above that.
Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
Start moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.